Security Snapshot

Jazz Pharmaceuticals plc - SHS USD (JAZZ) Institutional Ownership

CUSIP: G50871105

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

570

Shares (Excl. Options)

61,590,236

Price

$170.00

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / SHS USD
Symbol
JAZZ on Nasdaq
Price per share
$189.05
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
61,590,236
Total reported value
$10,461,399,585
% of total 13F portfolios
0.01%
Share change
+1,007,979
Value change
+$192,241,637
Number of holders
570
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • JAZZ - Jazz Pharmaceuticals plc - SHS USD is tracked under CUSIP G50871105.
  • 570 institutions reported positions in Q4 2025.
  • Schedule 13D/13G significant owner rows are not currently available.

What Changed

  • Holder count moved from 570 to 49 between Q4 2025 and Q1 2026.
  • Reported value moved from $10,461,399,585 to $124,017,631.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 570 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP G50871105?
CUSIP G50871105 identifies JAZZ - Jazz Pharmaceuticals plc - SHS USD in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

As of 31 Dec 2025, 570 institutional investors reported holding 61,590,236 shares of Jazz Pharmaceuticals plc - SHS USD (JAZZ).

Institutional Holders of Jazz Pharmaceuticals plc - SHS USD (JAZZ) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 656,040 $124,017,631 +$18,435,051 $189.05 49
2025 Q4 61,590,236 $10,461,399,585 +$192,241,637 $170.00 570
2025 Q3 60,646,127 $7,990,617,646 -$150,715,669 $131.80 498
2025 Q2 61,824,515 $6,561,677,298 +$172,218,482 $106.12 497
2025 Q1 59,973,813 $7,442,798,617 +$115,230,167 $124.15 545
2024 Q4 59,002,163 $7,265,494,814 +$147,830,867 $123.15 502
2024 Q3 57,597,455 $6,415,433,594 +$58,344,093 $111.41 469
2024 Q2 57,463,700 $6,133,341,626 -$38,433,148 $106.73 451
2024 Q1 57,711,183 $6,947,614,300 +$89,820,559 $120.42 475
2023 Q4 57,060,984 $7,017,863,210 -$56,981,989 $123.00 491
2023 Q3 56,530,271 $7,318,098,320 -$17,277,114 $129.44 482
2023 Q2 56,728,151 $7,039,068,770 -$22,114,573 $123.97 465
2023 Q1 56,681,319 $8,292,329,555 +$108,158,178 $146.33 462
2022 Q4 56,178,304 $8,948,272,058 -$100,056,709 $159.31 475
2022 Q3 56,928,016 $7,590,657,250 -$96,379,512 $133.29 443
2022 Q2 57,260,089 $8,932,716,610 +$138,065,500 $156.01 448
2022 Q1 56,748,008 $8,837,789,303 -$111,358,494 $155.67 437
2021 Q4 57,664,502 $7,350,056,970 +$21,422,030 $127.40 422
2021 Q3 56,879,540 $7,407,482,783 -$119,725,201 $130.21 422
2021 Q2 57,178,368 $10,156,395,395 +$780,868,772 $177.64 481
2021 Q1 53,127,709 $8,729,942,643 +$29,540,811 $164.37 435
2020 Q4 52,654,654 $8,685,222,791 -$294,935,573 $165.05 428
2020 Q3 54,543,371 $7,767,396,418 +$369,110,226 $142.59 382
2020 Q2 52,094,206 $5,741,576,836 +$270,141,092 $110.34 376
2020 Q1 49,800,360 $4,968,187,513 -$262,951,825 $99.74 397
2019 Q4 51,855,668 $7,738,313,733 +$162,667,912 $149.28 436
2019 Q3 50,956,459 $6,527,263,115 +$97,208,216 $128.14 397
2019 Q2 50,088,303 $7,125,707,525 +$206,804,403 $142.56 407
2019 Q1 51,378,205 $7,336,806,884 -$212,277,925 $142.95 415
2018 Q4 52,922,692 $6,549,889,371 -$427,140,677 $123.96 409
2018 Q3 55,400,378 $9,303,697,145 -$146,566,478 $168.13 397
2018 Q2 56,183,461 $9,670,926,964 +$435,954,554 $172.30 373
2018 Q1 53,679,721 $8,093,065,376 -$76,065,361 $150.99 320
2017 Q4 54,247,348 $7,295,659,971 -$66,672,908 $134.65 319
2017 Q3 54,642,574 $7,995,262,702 +$210,111,108 $146.25 299
2017 Q2 53,141,372 $8,263,546,157 +$374,758,650 $155.50 314
2017 Q1 52,283,523 $7,587,950,162 +$512,523,733 $145.13 302
2016 Q4 52,085,929 $5,676,848,580 -$158,899,374 $109.03 287
2016 Q3 53,391,287 $6,483,323,799 -$52,478,840 $121.48 317
2016 Q2 53,886,553 $7,614,644,976 -$43,527,577 $141.31 354
2016 Q1 54,554,481 $7,120,724,289 -$230,482,851 $130.55 330
2015 Q4 56,253,036 $7,906,867,974 -$16,787,687 $140.56 338
2015 Q3 56,363,725 $7,485,153,388 +$25,070,936 $132.81 350
2015 Q2 55,981,344 $9,856,454,549 +$619,952,018 $176.07 367
2015 Q1 52,457,739 $9,064,673,642 -$333,658,314 $172.79 352
2014 Q4 54,301,590 $8,892,764,640 +$176,201,808 $163.73 351
2014 Q3 53,225,671 $8,544,993,638 +$384,771,818 $160.56 320
2014 Q2 50,728,244 $7,457,848,518 +$45,563,248 $147.01 299
2014 Q1 50,472,408 $6,997,331,929 +$318,974,123 $138.68 310

Sponsored